Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03999879 · ClinicalTrials.gov registry record
PhosphoRus, Proton Imaging and Amyloid BuRdEn (PREPARE) ON AMYLOID BURDEN AND COGNITION
A clinical trial, sponsored by NYU Langone Health.
- Completed
- Registry status
- 37
- Enrollment target
NCT03999879: Completed study, sponsored by NYU Langone Health.
NCT03999879 is a clinical trial that has completed, run by NYU Langone Health. The registered enrollment target is 37 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03999879 has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 37 participants
- Enrollment target
Study Summary
Normal cells primarily produce energy with the help of the "mitochondria". These "small organs" are also called the "powerhouses of the cell" turn the sugars, fats and proteins that is eaten into forms of chemical energy that the body can use to carry on living. This process is called oxidative phosphorylation. In addition to the help from the mitochondria and oxidative phosphorylation, most cells can produce energy by lactic acid fermentation. This process is less energy efficient but faster and used by the brain, muscle or other organs under specific circumstances and energy demands, even in the presence of abundant oxygen. It is also called aerobic glycolysis. Aerobic glycolysis and oxidative phosphorylation are the two major mechanisms involved in brain energetics.
Primary Outcome
These 31P-MRSI data will differentiate PiB+ aMCI individuals from PiB+ NL individuals.
Interventions
- DIAGNOSTIC_TEST Measure of OxPhos upregulation
- DIAGNOSTIC_TEST lactate (measured with 1H-MRSI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2023-02-24 |
What the finished NCT03999879 record still lists
NCT03999879 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 37 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Measure of OxPhos upregulation is the first listed.
NCT03999879 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03999879 about?
NCT03999879 is a clinical study titled "PhosphoRus, Proton Imaging and Amyloid BuRdEn (PREPARE) ON AMYLOID BURDEN AND COGNITION". Normal cells primarily produce energy with the help of the "mitochondria". These "small organs" are also called the "powerhouses of the cell" turn the sugars, fats and proteins that is eaten into forms of chemical energy that the body can use to carry on living. This process is called oxidative phos...
What is the current status of trial NCT03999879?
This trial is currently completed. The enrollment target is 37 participants. The study started on 2019-05-01. Estimated completion is 2023-02-24.
What interventions are being tested in trial NCT03999879?
The interventions under investigation include: Measure of OxPhos upregulation (DIAGNOSTIC_TEST), lactate (measured with 1H-MRSI) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03999879?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI